A
Ana Aparicio
Researcher at University of Texas MD Anderson Cancer Center
Publications - 164
Citations - 9365
Ana Aparicio is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 41, co-authored 136 publications receiving 7894 citations. Previous affiliations of Ana Aparicio include University of Southern California & Stanford University.
Papers
More filters
Journal ArticleDOI
Epigenetics in human disease and prospects for epigenetic therapy
TL;DR: Great potential lies in the development of ‘epigenetic therapies’ — several inhibitors of enzymes controlling epigenetic modifications, specifically DNA methyltransferases and histone deacetylases, have shown promising anti-tumorigenic effects for some malignancies.
Journal ArticleDOI
Neoplastic meningitis
Ana Aparicio,Marc C. Chamberlain +1 more
TL;DR: The inclusion of concomitant systemic therapy may benefit patients with meningitis and may obviate the need for intra-CSF chemotherapy as discussed by the authors, which is a common problem in neurooncology, occurring in approximately 5% of all patients with cancer.
Journal ArticleDOI
Aggressive Variants of Castration-Resistant Prostate Cancer
Himisha Beltran,Scott A. Tomlins,Ana Aparicio,Vivek K. Arora,David S. Rickman,Gustavo Ayala,Jiaoti Huang,Lawrence D. True,Martin E. Gleave,Howard R. Soule,Christopher J. Logothetis,Mark A. Rubin +11 more
TL;DR: Patients meeting clinical criteria of anaplastic prostate cancer have been shown to predict for poor prognosis, and these patients may be considered for platinum-based chemotherapy treatment regimens, so understanding variants within the spectrum of advanced prostate cancer has important diagnostic and treatment implications.
Journal ArticleDOI
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Ana Aparicio,Andrea L. Harzstark,Paul G. Corn,Sijin Wen,Sijin Wen,John C. Araujo,Shi-Ming Tu,Lance C. Pagliaro,Jeri Kim,Randall E. Millikan,Charles J. Ryan,Nizar M. Tannir,Amado J. Zurita,Paul Mathew,Paul Mathew,Wadih Arap,Patricia Troncoso,Peter F. Thall,Christopher J. Logothetis +18 more
TL;DR: The hypothesis that patients with “anaplastic” prostate cancer are a recognizable subset characterized by a high response rate of short duration to platinum-containing chemotherapies, similar to SCPC is supported.
Journal ArticleDOI
Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
Eleni Efstathiou,Eleni Efstathiou,Mark Titus,Sijin Wen,Anh Hoang,Maria Karlou,Robynne G. Ashe,Shi Ming Tu,Ana Aparicio,Patricia Troncoso,James L. Mohler,Christopher J. Logothetis +11 more
TL;DR: The observed subcellular shift of AR from the nucleus and increased testosterone concentration provide the first evidence in humans that enzalutamide suppresses AR signaling while inducing an adaptive feedback, which is linked to a pretreatment androgen-signaling signature.